Dr. Zhang on the ARCHES Trial in Prostate Cancer

Tian Zhang, MD
Published: Thursday, Nov 30, 2017



Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

The ARCHES trial is investigating enzalutamide (Xtandi) in the maintenance setting for patients with metastatic castration-sensitive disease.

It is enrolling patients with metastatic castration-sensitive prostate cancer and randomizes them to either enzalutamide or placebo. The standard of care for these patients was androgen deprivation therapy alone before the LATITUDE or CHAARTED data was published, explains Zhang.
 


Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

The ARCHES trial is investigating enzalutamide (Xtandi) in the maintenance setting for patients with metastatic castration-sensitive disease.

It is enrolling patients with metastatic castration-sensitive prostate cancer and randomizes them to either enzalutamide or placebo. The standard of care for these patients was androgen deprivation therapy alone before the LATITUDE or CHAARTED data was published, explains Zhang.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x